PremiumPre-EarningsERAS Earnings this Week: How Will it Perform? Erasca assumed with an Overweight at Morgan Stanley Erasca’s Promising Oncology Advances: Buy Rating Backed by Strong Market Potential and Competitive Edge PremiumThe FlyErasca reports Q3 EPS (11c), consensus (17c) Erasca announces clinical progress for naporafenib Erasca to present preliminary SEACRAFT-1 Phase 1 data PremiumThe FlyErasca price target lowered to $5 from $8 at H.C. Wainwright Erasca 86.5M share Secondary priced at $1.85 Erasca announces strategic in-licensing of RAS-targeting franchise 
